Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Nirogy Therapeutics

Request full access

Developing novel small molecules to target cellular transporters

Natick, United StatesBiotech & Life Sciences

About Nirogy Therapeutics

Nirogy Therapeutics, Inc. is a biotechnology firm that develops small-molecule drugs targeting cellular transporters for the treatment of diseases like cancer and autoimmune conditions. Founded in 2013 by Vincent Sandanayaka and Jaime Escobedo, the company was formerly known as Nirogyone Therapeutics. The company's name, derived from Sanskrit, means "without illness," reflecting its mission to address unmet medical needs. Vincent Sandanayaka, who serves as the President and CEO, has an extensive background in the pharmaceutical industry. Another co-founder, Ronald DePinho, serves on the Sporos strategic advisory board.

The company's core business revolves around its drug discovery platform, which leverages computational modeling, medicinal chemistry, and biology to target solute carrier (SLC) transporters. These proteins, embedded in cell membranes, are crucial for physiological functions such as nutrient uptake and waste disposal, which are often dysregulated in various diseases. Historically, SLCs have been difficult to drug due to their complex structures. Nirogy's platform is designed to overcome these challenges and has the potential to address over 450 druggable targets.

The business model is focused on developing a pipeline of first-in-class medicines. The company generates revenue through research grants and venture capital funding to advance its programs through preclinical and clinical development, with the ultimate goal of commercializing its therapies. In January 2021, Nirogy officially launched with a $16.5 million Series A financing round co-led by Santé Ventures and Sporos Bioventures. This followed a $1.94 million grant in August 2020. The company's lead program targets monocarboxylate transporters (MCTs) to inhibit lactate transport in cancer cells. This approach has a dual effect: it directly hinders cancer cell metabolism and also enhances anti-tumor immunity by altering the tumor microenvironment. Preclinical studies have shown that these inhibitors are effective both as a standalone therapy and in combination with other immunotherapies. The company had aimed to advance this lead program into clinical trials in 2022. Beyond oncology, Nirogy's pipeline includes programs for immunology. According to a PitchBook profile, the company is listed as 'Out of Business' as of December 31, 2024.

Source: Dealroom company data

At a glance

Status
Operational
Open positions
None listed
Dealroom signal
3.1/100
Industry
Health
Sub-industry
BioTechnology
Sector
Biotechnology, Biotech and Pharma, Hard Tech, DT and LS
Business model
Manufacturing
Client focus
B2B
Links
Website

Funding history

2 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
SERIES A✓Equity / VC Jan 2021 $17M $66M Sporos Bioventures · Sante Ventures —
GRANT✓Other financing Sep 2020 $2M — Undisclosed —
Showing the latest 2 of 2 recorded eventsBook a demo for the full funding history →

Growth signals

Nirogy Therapeutics website traffic

Latest recorded traffic for Nirogy Therapeutics is 220 monthly website visits, down 48.8% over the last three months.

Latest monthly visits220 3-month web change-48.8%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Nirogy Therapeutics in the Natick ecosystem

Live from Dealroom

The Nirogy Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

2 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A2 investors entered at this stage

  • Sporos Bioventures
  • Sante Ventures
Founders Hidden — book a demo/100 quality score
Key operators Hidden — book a demo quality score
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
🇺🇸 United States · Natick HQ
Book a demo for the full country breakdown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Nirogy Therapeutics on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Nirogy Therapeutics’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.